Trial Profile

A phase 2a clinical trial of TJ210 in combination with toripalimab

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 26 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Izastobart (Primary) ; Toripalimab (Primary)
Indications Solid tumours
Focus Therapeutic Use
Sponsors NovaBridge Biosciences

Most Recent Events

29 Oct 2025 According to NovaBridge Biosciences media release, I-MAB Biopharma has changed its name to NovaBridge Biosciences.
06 Apr 2022 New trial record
29 Mar 2022 According to an I-MAB Biopharma media release, IND for phase 2a clinical trial of TJ210 in combination with toripalimab (a marketed PD-1 antibody) is planned for submission in Q2 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com